Skip to main content

Sheep Diseases

Volume 450: debated on Wednesday 25 October 2006

To ask the Secretary of State for Environment, Food and Rural Affairs if his Department will assess the merits of using the Australian vaccination for caseous lymphadenitis in sheep. (95952)

Commercial vaccines to protect against caseous lymphadenitis (CLA) are available in several countries including Australia. None of the commercially produced vaccines are currently authorised for marketing in the UK; however a veterinary surgeon may apply for a Special Import Certificate to import vaccine for use in a particular infected flock. Glanvac, a vaccine used in Australia has been imported into the UK for the control of CLA infection in both sheep and goats.

The widespread availability of a CLA vaccine in GB would depend on a commercial decision by a vaccine manufacturer to apply for a Marketing Authorisation; however if CLA vaccine were to become generally available, its use could suppress clinical disease in infected flocks without eradicating infection. As vaccinated animals can transmit infection, the use of vaccine in the absence of health certification could increase the risk of spread of infection.